IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. 
Effects of Growth Hormone Releasing Hormone in HIV
This study has been completed.
Sponsor:
Massachusetts General Hospital
Information provided by (Responsible Party):
Steven K. Grinspoon, MD, Massachusetts General Hospital
ClinicalTrials.gov Identifier:
NCT01263717
First received: December 16, 2010
Last updated: October 10, 2014
Last verified: October 2014
- Full Text View
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Purpose
HIV-infection and its treatment are often associated with an increase in belly fat, as well as abnormal cholesterol and problems metabolizing sugar. People with HIV infection and increased belly fat often have decreased growth hormone (GH) levels. Low GH levels may contribute independently to increased belly fat and to increased cardiovascular risk through effects on sugar metabolism, inflammation, and other mechanisms. Tesamorelin, a growth hormone releasing hormone (GHRH) analogue, has been shown to to reduce belly fat in patients with HIV-associated abdominal fat accumulation. However, the effects of tesamorelin on fat accumulation in the liver and muscle, sugar metabolism, and cardiovascular health are not yet known. The current study is designed to determine the effects of tesamorelin treatment on fat accumulation in the muscle and liver, insulin sensitivity and sugar metabolism, and markers of cardiovascular health including blood vessel thickness (carotid intima media thickness [cIMT]) and markers of inflammation in the body. The investigators hypothesize that tesamorelin will decrease fat accumulation in the liver and muscle and will decrease markers of inflammation, with either neutral or beneficial effects on glucose metabolism.
| Condition | Intervention |
|---|---|
| HIV HIV Lipodystrophy | Drug: tesamorelin Drug: placebo |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Intervention Model: Parallel Assignment Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor) Primary Purpose: Treatment |
| Official Title: | Effects of Growth Hormone Releasing Hormone on Fat Redistribution, Cardiovascular Indices, and Growth Hormone Secretion in HIV Lipodystrophy |
Resource links provided by NLM:
Further study details as provided by Steven K. Grinspoon, MD, Massachusetts General Hospital:
Primary Outcome Measures:
- Liver Fat [ Time Frame: 6 months ]Hepatic fat as measured by magnetic resonance (MR) spectroscopy, and expressed by normalizing lipid to water and expressing as a percent (lipid-to-water percent).
- Visceral Adipose Tissue [ Time Frame: 6 months ]Change in visceral adipose tissue area as measured by single-slice computed tomography (CT) scan at the L4 vertebra.
Secondary Outcome Measures:
- Intramyocellular Lipid [ Time Frame: 6 months ]Intramyocellular lipid (IMCL) as measured by magnetic resonance (MR) spectroscopy of the calf. Soleus IMCL normalized to creatinine (IMCL/Cr based on areas determined by spectroscopy) was measured. The change over 6 months is reported.
- Endogenous Growth Hormone Secretion [ Time Frame: 6 months ]Endogenous growth hormone (GH) concentrations measured by overnight frequent blood sampling every 20 minutes. Mean overnight GH concentration is given.
- Insulin Sensitivity [ Time Frame: 6 months ]In a subgroup of 1/2 of the subjects, euglycemic hyperinsulinemic clamp will be performed to assess insulin-stimulated glucose uptake. Insulin stimulated glucose uptake (M) calculated using the method of DeFronzo is shown.
- HbA1c [ Time Frame: 6 months ]Hemoglobin A1c.
- Insulin Like Growth Factor 1 (IGF-I) [ Time Frame: 6 months ]Insulin Like Growth Factor 1 (IGF-I).
- Lipid Panel [ Time Frame: 6 months ]Fasting lipids. Triglyceride value is given.
- Carotid Intimal Medial Thickness (cIMT) [ Time Frame: 6 months ]Carotid Intimal Medial Thickness (cIMT).
- Glucose Tolerance [ Time Frame: 6 months ]Glucose tolerance as measured by standard oral glucose tolerance test. 2-hour glucose is given.
- Adiponectin [ Time Frame: 6 months ]adiponectin.
- Hemostatic Markers [ Time Frame: 6 months ]Tissue plasminogen activator (tPA) and plasminogen activator inhibitor-1 (PAI-1) measured in serum.
| Enrollment: | 54 |
| Study Start Date: | December 2010 |
| Study Completion Date: | February 2014 |
| Primary Completion Date: | February 2014 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: Tesamorelin
Tesamorelin (growth hormone releasing hormone) 2mg daily given subcutaneously x 6 months during randomized phase, followed by 6 months of open-label tesamorelin at same dose
|
Drug: tesamorelin
Tesamorelin (growth hormone releasing hormone) 2mg daily given by subcutaneous injection x 6 months during randomized phase, followed by 6 months of open-label tesamorelin at same dose
Other Name: Egrifta, growth hormone releasing hormone, TH9507
|
|
Placebo Comparator: Placebo (inactive injection)
Placebo 2mg daily given subcutaneously for the first 6 months of the study, followed by 6 months of tesamorelin (growth hormone releasing hormone) 2mg daily during an open label phase
|
Drug: placebo
Placebo 2mg daily given by subcutaneous injection for the first 6 months of the study, followed by an open-label phase of 6 months of tesamorelin (growth hormone releasing hormone) treatment, 2mg daily given by subcutaneous injection
|
Eligibility| Ages Eligible for Study: | 18 Years to 65 Years (Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Men and women age 18-65
- Previously diagnosed HIV infection
- Stable antiviral regimen for at least 12 weeks prior to enrollment
- WC>95 cm and WHR>0.94 for male, WC>94 cm and WHR>0.88 for female occurring in the context of treatment for HIV disease
- Subjective evidence of at least one of the following recent changes, occurring during the treatment of HIV disease: increased abdominal girth, relative loss of fat in the extremities, or relative loss of fat in the face
- For female subjects 40yo or older, negative mammogram within one year of baseline
Exclusion Criteria:
- Use of anti-diabetic agents, Megace, testosterone or any steroid use within 6 months of the study. Stable use of testosterone (> 6 mos) at dose equivalent to 200 mg IM q 2 weeks or < 10g/day to skin will be permitted.
- Use of GH or GHRH within the past 6 months
- Change in lipid lowering or antihypertensive regimen within 3 months of screening
- Fasting blood sugar > 126 mg/dL, SGOT > 2.5 times ULN, HgB < 12.0 g/dL, creatinine > 1.4 mg/dL, CD4 count < 200
- Severe chronic illness or active malignancy or history of pituitary malignancy or history of colon cancer
- For men, history of prostate cancer or evidence of prostate malignancy by PSA > 5 ng/mL
- Prior history of hypopituitarism, head irradiation or any other condition known to affect the GH axis
- For women, positive urine hCG
- Oral contraceptives, depo provera or combined progesterone-estrogen injections, transdermal contraceptive patches, estrogen or progestin coated IUD's within 6 months of the study.
- Routine MRI exclusion criteria such as the presence of a pacemaker or cerebral aneurysm clip.
Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01263717
Please refer to this study by its ClinicalTrials.gov identifier: NCT01263717
Locations
| United States, Massachusetts | |
| Massachusetts General Hospital | |
| Boston, Massachusetts, United States, 02114 | |
Sponsors and Collaborators
Massachusetts General Hospital
Investigators
| Principal Investigator: | Steven Grinspoon, MD | Massachusetts General Hospital |
More Information
Publications:
| Responsible Party: | Steven K. Grinspoon, MD, Professor of Medicine, Massachusetts General Hospital |
| ClinicalTrials.gov Identifier: | NCT01263717 History of Changes |
| Other Study ID Numbers: |
2007p-000638 |
| Study First Received: | December 16, 2010 |
| Results First Received: | September 8, 2014 |
| Last Updated: | October 10, 2014 |
Keywords provided by Steven K. Grinspoon, MD, Massachusetts General Hospital:
|
HIV lipodystrophy tesamorelin Egrifta growth hormone releasing hormone |
Additional relevant MeSH terms:
|
Lipodystrophy Skin Diseases, Metabolic Skin Diseases Lipid Metabolism Disorders Metabolic Diseases |
Hormones Growth Hormone-Releasing Hormone Hormones, Hormone Substitutes, and Hormone Antagonists Physiological Effects of Drugs |
ClinicalTrials.gov processed this record on June 23, 2017